Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V, Rosenwirth B
Sandoz Forschungsinstitut GmbH, Vienna, Austria.
J Virol. 1995 Apr;69(4):2451-61. doi: 10.1128/JVI.69.4.2451-2461.1995.
Cyclosporins, in particular the nonimmunosuppressive derivative SDZ NIM 811, exhibit potent anti-human immunodeficiency virus type 1 (HIV-1) activity in vitro. SDZ NIM 811 interferes at two stages of the viral replication cycle: (i) translocation of the preintegration complex to the nucleus and (ii) production of infectious virus particles. Immunosuppressive activity is not correlated with anti-HIV-1 activity of cyclosporins. However, binding to cyclophilin A, the major cellular receptor protein of cyclosporins, is a prerequisite for HIV inhibition: all structural changes of the cyclosporin A molecule leading to loss of affinity to cyclophilin abolished the antiviral effect. Cyclosporin derivatives did not interact directly with HIV-1 proteins; cyclophilin was the only detectable receptor protein for antivirally active cyclosporins. There is no evidence that inhibition of HIV occurs via a gain of function of cyclophilin in the presence of cyclosporins: the complex of cyclophilin A with SDZ NIM 811 does not bind to calcineurin or to any other viral or cellular proteins under conditions in which calcineurin binding to the cyclophilin A-cyclosporin A complex is easily detectable. Thus, the loss of function caused by binding of cyclosporins to cyclophilin seems to be sufficient for the anti-HIV effect. Cyclophilin A was demonstrated to bind to HIV-1 p24gag, and the formation of complexes was blocked by cyclosporins with 50% inhibitory concentrations of about 0.7 microM. HIV-2 and simian immunodeficiency virus are only weakly or not at all inhibited by cyclosporins. For gag-encoded proteins derived from HIV-1, HIV-2, or simian immunodeficiency virus particles, cyclophilin-binding capacity correlated with sensitivity of the viruses to inhibition by cyclosporins. Cyclophilin A also binds to HIV-1 proteins other than gag-encoded proteins, namely, p17gag, Nef, Vif, and gp120env; the biological significance of these interactions is questionable. We conclude that HIV-1 Gag-cyclophilin A interaction may be essential in HIV-1 replication, and interference with this interaction may be the molecular basis for the antiviral activity of cyclosporins.
环孢菌素,尤其是非免疫抑制性衍生物SDZ NIM 811,在体外表现出强大的抗人类免疫缺陷病毒1型(HIV-1)活性。SDZ NIM 811在病毒复制周期的两个阶段发挥作用:(i)前整合复合物向细胞核的转运;(ii)感染性病毒颗粒的产生。环孢菌素的免疫抑制活性与抗HIV-1活性无关。然而,与环孢菌素的主要细胞受体蛋白亲环蛋白A结合是抑制HIV的前提条件:环孢菌素A分子导致与亲环蛋白亲和力丧失的所有结构变化都会消除抗病毒作用。环孢菌素衍生物不与HIV-1蛋白直接相互作用;亲环蛋白是具有抗病毒活性的环孢菌素唯一可检测到的受体蛋白。没有证据表明在存在环孢菌素的情况下,HIV的抑制是通过亲环蛋白功能的增强实现的:在亲环蛋白A与环孢菌素A复合物结合钙调神经磷酸酶很容易检测到的条件下,亲环蛋白A与SDZ NIM 811的复合物不与钙调神经磷酸酶或任何其他病毒或细胞蛋白结合。因此,环孢菌素与亲环蛋白结合导致的功能丧失似乎足以产生抗HIV作用。已证明亲环蛋白A与HIV-1 p24gag结合,环孢菌素可阻断复合物的形成,半数抑制浓度约为0.7微摩尔。HIV-2和猴免疫缺陷病毒仅被环孢菌素微弱抑制或根本不被抑制。对于源自HIV-1、HIV-2或猴免疫缺陷病毒颗粒的gag编码蛋白,亲环蛋白结合能力与病毒对环孢菌素抑制的敏感性相关。亲环蛋白A还与除gag编码蛋白之外的HIV-1蛋白结合,即p {17gag}、Nef、Vif和gp {120env};这些相互作用的生物学意义尚不确定。我们得出结论,HIV-1 Gag与亲环蛋白A的相互作用可能在HIV-1复制中至关重要,干扰这种相互作用可能是环孢菌素抗病毒活性的分子基础。